Crossmark

Modulating gut microbiota to enhance anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: the role of Lactobacillus kefiranofaciens and SOCS3 regulation

Crossref DOI link: https://doi.org/10.1038/s41388-026-03701-3

Published Online: 2026-04-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lv, Caihong

Du, Junli

Feng, Wanqing

Zhou, Rang

Chen, Jie https://orcid.org/0009-0009-0587-1888
Funding

Funding for this research was provided by:

Natural Science Foundation of Heilongjiang Province (20237118)
License Information

Text and Data Mining valid from 2026-04-27

Version of Record valid from 2026-04-27
More Information

Article History

Received: 16 October 2024

Revised: 19 January 2026

Accepted: 18 February 2026

First Online: 27 April 2026

Competing interests

: The author declares no competing interests.

: All animal experiments were conducted following the guidelines approved by the Animal Care and Use Committee of our institution (Approval Number: SSH9H-2024-A1039-SB). Clinical studies were not involved in this research.

Document is current

Any future updates will be listed below